Who are intermittent pivotal βL-AB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ceftazidime-avibactam + Aztreonam, Colistin/Polymyxin B + Sulbactam, Piperacillin Sodium and Sulbactam Sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intermittent-pivotal-l-ab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

intermittent pivotal βL-AB — Competitive Intelligence Brief

intermittent pivotal βL-AB (intermittent pivotal βL-AB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: β-lactamase inhibitor. Area: Infectious disease.

marketed β-lactamase inhibitor β-lactamase Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

intermittent pivotal βL-AB (intermittent pivotal βL-AB) — Assistance Publique - Hôpitaux de Paris. Intermittent pivotal βL-AB works by inhibiting the beta-lactamase enzyme.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
intermittent pivotal βL-AB TARGET	intermittent pivotal βL-AB	Assistance Publique - Hôpitaux de Paris	marketed	β-lactamase inhibitor	β-lactamase
Ceftazidime-avibactam + Aztreonam	Ceftazidime-avibactam + Aztreonam	National University of Singapore	marketed	β-lactam antibiotic combination with β-lactamase inhibitor	Bacterial penicillin-binding proteins; β-lactamases
Colistin/Polymyxin B + Sulbactam	Colistin/Polymyxin B + Sulbactam	National University of Singapore	marketed	Polymyxin antibiotic + β-lactamase inhibitor combination	Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Piperacillin Sodium and Sulbactam Sodium	Piperacillin Sodium and Sulbactam Sodium	Xiangbei Welman Pharmaceutical Co., Ltd	marketed	β-lactam antibiotic with β-lactamase inhibitor	Penicillin-binding proteins; bacterial β-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (β-lactamase inhibitor class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intermittent pivotal βL-AB — Competitive Intelligence Brief. https://druglandscape.com/ci/intermittent-pivotal-l-ab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab